Acute retinal pigment epithelial tear following intravitreal bevacizumab (Avastin) injection for occult choroidal neovascularisation secondary to age related macular degeneration [5]

British Journal of Ophthalmology

Volumn 90, Issue 9, 2006, Pages 1207-1208

  Meyer, Garsten H ^a   Mennel, S ^a   Schmidt, J C ^a   Kroll, P ^a  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB;

ADULT; AGED; CASE REPORT; CLINICAL FEATURE; FEMALE; HUMAN; LETTER; MALE; PIGMENT EPITHELIUM; PRIORITY JOURNAL; RETINA MACULA DEGENERATION; RETINA TEAR; SUBRETINAL NEOVASCULARIZATION;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; CHOROIDAL NEOVASCULARIZATION; HUMANS; INJECTIONS; MACULAR DEGENERATION; MALE; MIDDLE AGED; PIGMENT EPITHELIUM OF EYE;

EID: 33746276707     PISSN: 00071161     EISSN: None     Source Type: Journal    
DOI: 10.1136/bjo.2006.093732     Document Type: Letter

References (6)

1. Gelisken F, Inhoffen W, Partsch M, et al. Retinal pigment epithelial tear after photodynamic therapy for choroidal neovascularization. Am J Ophthalmol 2001;131:518-20.
2. Rosenfeld PJ, Moshfeghi AA, Puliafito CA. Optical coherence tomography findings after an intravitreal injection of bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmic Surg Lasers Imaging 2005;36:331-5.
3. Meyer CH, Toth CA. Retinal pigment epithelial tear with vitreomacular attachment: a novel pathogenic feature. Graefes Arch Clin Exp Ophthalmol 2001;239:325-33.
4. Hesse L. Tissue-type plasminogen activator. An enzyme with multiple uses in ophthalmology. Ophthalmologe 1997;94:366-71.
5. Gragoudas ES, Adamis AP, Cunningham ET Jr, et al. VEGF Inhibition Study in Ocular Neovascularization Clinical Trial Group. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 2004;351:2805-16.
6. Kroll P, Meyer CH. Which treatment is best for which AMD patient? [editorial]. Br J Ophthalmol 2006;90:128-30.